Skip to main content

Day: March 22, 2025

HII’s Ingalls Shipbuilding Celebrates Apprentice School Graduates

Written by Customer Service on . Posted in Public Companies.

PASCAGOULA, Miss., March 22, 2025 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division celebrated its newest class of apprentice graduates during a ceremony at the shipyard today. The event recognized the hard work and dedication of the graduates who have completed the three-to four-year program combining classroom instruction with hands-on shipbuilding experience. Ingalls Shipbuilding President Brian Blanchette provided remarks at the ceremony and praised the graduates for their commitment and contribution to the company’s shipbuilding legacy. “Completing the Ingalls apprentice program is no small feat and it reflects years of dedication, hard work and persistence,” Blanchette said. “The training our apprentices received wasn’t just about mastering skills like welding and fitting — it was about building the foundation...

Continue reading

Financière de Tubize – Annual report 2024

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Annual Report 2024Regulated information 22 March 2025 The board of directors of Financière de Tubize has established the 2024 annual report. This report is available on the website www.financiere-tubize.beProfit for the financial year: € 90.1 million (€ 88.2 million in 2023, + 2,2%), Reduction of outstanding bank borrowings from € 79.2 million at 31 December 2023 to € 41.3 million at 31 December 2024, Acquisition, in 2024, of 53,706 UCB shares, increasing the holding of the Company in UCB from 36.24% on 31 December 2023 to 36.27% on 31 December 2024.If the general shareholders meeting of 25 April 2025 approves the 2024 annual accounts, including the proposed result appropriation, a gross dividend of € 1.04 (compared to €0.97 for financial year 2023, an increase of 7.2%) will be payable as from 5 May 2025 onwards at the offices, seats...

Continue reading

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Written by Customer Service on . Posted in Public Companies.

Company AnnouncementAbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle) Genmab categorically refutes allegations and will vigorously defend the companyCOPENHAGEN, Denmark; March 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today thatAbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US Co.; ProfoundBio (Suzhou) Co., Ltd.; and former AbbVie employees as defendants. AbbVie alleges that the defendants have misappropriated AbbVie’s alleged trade secrets relating to the use of disaccharides to improve the hydrophilicity of drug-linkers in antibody-drug conjugates (ADCs) in connection with rinatabart sesutecan (Rina-S™) and other ADC pipeline products of ProfoundBio....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.